Company: SXTPW
Filing Date: 2025-09-05
Form Type: 424B5
Source: 0001213900-25-085050
Chunk: 8

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-09-05
Form: 424B5
Chunk 8
---
 evaluate Celgosivir in additional non-clinical disease models before making a decision regarding clinical development.

| 14 | According to the Centers for Disease Control and Prevention.                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 15 | Dow and Smith New Microb New Infect 2022;45:100964.                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 16 | According to data from the Organ Transplant and Procurement Network, Dsouza et al Biology of Blood and Bone Marrow Transplantation 202;26: e177-e182, Lymphoma Research Foundation, and the American Cancer Society, and in reference to treatment guidelines described by Fishman et al Clinical Transplantation. 2019;33:e13587, the Cancer Network and Cooper et al Journal of the National Comprehensive Cancer Network 2016;14:882-913 and (iv) Los Arcos et al Infection (2021) 49:215–231. |
| 17 | Aguilar-Guisado et al Clin Transplant 2011;25:E629–38; Mace et al MMWR 202;70:1–35.                                                                                                                                                                                                                                                                                                                                                                                                               |
| 18 | Queener et al JID 1997;165:764-768; Dow and Smith New Microb New Infect 2022;45:100964                                                                                                                                                                                                                                                                                                                                                                                                            |

<div align='center'>S-4</div>

More information about our products is provided in the next section, and the status of various development efforts for the above-mentioned diseases is outlined in Figure A, below. Figure A Products Arakoda (Tafenoquine) for malaria prevention We entered into a cooperative research and development agreement with the United States Army in 2014 to complete development of Arakoda for prevention of malaria. 21With the U.S. Army, and other private sector entities as partners, we coordinated the execution of two clinical trials, development of a full manufacturing package, gap-filling non-clinical studies, compilation of a full regulatory dossier, successful defense of our program at an FDA advisory committee meeting and submitted a new drug application (“NDA”) to the FDA in 2018. The history of that collaboration has been publicly communicated by the U.S. Army. 22

| 19 | According to the European Centre for Disease Prevention and Control                                                                                                                                                                                                                                                                                                           |
| 20 | According to the Centers for Disease Control and Prevention.                                                                                                                                                                                                                                                                                                                  |
| 21 | In 2014, we signed a